Orchestra BioMed (OBIO) director adds 665 shares in open-market buy

Rhea-AI Filing Summary

Orchestra BioMed Holdings director Aryeh Jason made a small open-market purchase of company stock. On May 18, 2026, he bought 665 shares of common stock at a weighted average price of about $3.75–$3.76 per share. After this transaction, he directly owns 118,118 shares.

Insider Trade Summary

Net Buyer: 665 shares ($2,494)

Net Buy 1 txn

Insider Aryeh Jason

Role null

Bought 665 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	665	$3.75	$2K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 118,118 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 665 shares Purchase price: $3.75–$3.76 per share Shares owned after trade: 118,118 shares +1 more

4 metrics

Shares purchased 665 shares Open-market buy on May 18, 2026

Purchase price $3.75–$3.76 per share Weighted average price range for the transaction

Shares owned after trade 118,118 shares Direct holdings following the reported purchase

Net share change 665 shares Net buy according to transaction summary

Key Terms

open-market purchase, weighted average price, Common Stock, par value $0.0001 per share

3 terms

open-market purchase financial

"The Form 4 classifies the transaction as an open-market purchase of common stock."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The filing specifies that the reported purchase price is a weighted average, with individual trades executed between $3.75 and $3.76."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock, par value $0.0001 per share financial

"Common Stock, par value $0.0001 per share"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aryeh Jason

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PENNSYLVANIA 18938

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	05/18/2026		P		665	A	$3.75(1)	118,118	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.75 to $3.76. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Andrew Taylor, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aryeh Jason report for Orchestra BioMed (OBIO)?

Director Aryeh Jason reported an open-market purchase of 665 shares of Orchestra BioMed common stock. The transaction occurred on May 18, 2026, reflecting a direct increase in his personal holdings in the company’s shares.

At what price did Aryeh Jason buy OBIO shares in this Form 4?

He purchased the 665 Orchestra BioMed shares at a weighted average price between $3.75 and $3.76 per share. The filing notes multiple trades within this range and offers full pricing details upon request to relevant parties.

How many Orchestra BioMed (OBIO) shares does Aryeh Jason own after this transaction?

Following the reported purchase, Aryeh Jason directly owns 118,118 shares of Orchestra BioMed common stock. This total includes the newly acquired 665 shares disclosed in the May 18, 2026 open-market transaction.

Was Aryeh Jason’s OBIO trade an open-market purchase or another type of transaction?

The Form 4 classifies the transaction as an open-market purchase of common stock. This means he bought shares on the market, rather than receiving them through grants, option exercises, gifts, or other non-market mechanisms.

Does the Form 4 for OBIO mention a weighted average price for the shares bought?

Yes. The filing specifies that the reported purchase price is a weighted average, with individual trades executed between $3.75 and $3.76. It states full per-trade price details are available to the issuer, investors, or regulators upon request.